THE Therapeutic Goods
Administration has today invited
comments from interested parties
on advisory statements for
cetirizine when included in nonprescription
medicines for oral use.
The move follows last Oct’s TGA
decision which downscheduled
packs containing five 10mg tablets
of cetirizine for the treatment of
seasonal allergic rhinitis to be S2
(available without prescription).
The move came with a
recommendation that the labelling
for the product be updated, and
the OTC Medicines Evaluation
Section of the TGA has proposed
that a warning be added that the
medication may cause drowsiness
and increase the effects of alcohol.
The proposal also includes a
warning to check with a doctor
or pharmacist if pregnant or
breasfeeding.
A full consultation document has
been made available on the TGA
website, and interested parties are
invited to respond by the close of
business on Fri 03 May.The above article was sent to subscribers in Pharmacy Daily's issue from 05 Apr 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Apr 13
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.